Bacitracin

Therapeutic

Indicated in topical formulations for acute and chronic localized skin infections

Structural features

SMILES

CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC

Sequence

XLeIKXIfHdN

Molar mass

1422.71 g/mol

Constitutional members:

11

Natural amino acids

6

D-Amino acids

4

N-terminus

1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl

C-terminus

cycle

Cyclic

yes

Members/cycle

7

Bond to form cycle

head-to-side chain (amide Lys-Asn)

Lipidation

no

Glycosylation

no

Route of administration

IM, TOPICAL, OPHTALMIC, ORAL

Terminal half-life

-

Protein binding

-

Absorption and Bioavailability

Topical, ophthalmic, and oral formulations of bacitracin are poorly absorbed systemically. Intramuscular bacitracin is readily and completely absorbed

References